secwatch.observer — SEC 8-K summary
======================================

Issuer:     Valion Bio, Inc. (VBIO)
CIK:        0001787740
Form:       8-K
Filed at:   2024-09-17T23:59:59+00:00
Accession:  0000950170-24-107032
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tivic Health Partners with Fletcher Spaght to Accelerate ncVNS Commercial Strategy
--------------------------------------------------------------------------------

- Partnered with Fletcher Spaght, a healthcare growth strategy firm, to develop commercial strategy for non-invasive cervical vagus nerve stimulation (ncVNS).
- Fletcher Spaght identified ~30 potential use cases in neurologic, cardiac, psychiatric, and autonomic diseases.
- Global VNS market projected to grow from $8.59B (2021) to $21.3B (2030) at 10.6% CAGR; peripheral nerve stimulation at 35% CAGR.
- Tivic completed Phase 1 trial showing strong physiological effects in neurological, cardiac, and autonomic systems.
- Company expects insights to drive clinical strategy and product development in 2025 and beyond.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787740/000095017024107032/0000950170-24-107032-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787740/000095017024107032/tivc-20240916.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-107032

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer